These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36655117)

  • 21. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
    Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.
    Nguyen MA; Kosenko T; Lagace TA
    J Lipid Res; 2014 Feb; 55(2):266-75. PubMed ID: 24296664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biological relevance of PCSK9: when less is better….
    Mbikay M; Chrétien M
    Biochem Cell Biol; 2022 Jun; 100(3):189-198. PubMed ID: 35263196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
    Shen L; Peng HC; Nees SN; Zhao SP; Xu DY
    FEBS Lett; 2013 May; 587(9):1271-4. PubMed ID: 23499248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form.
    Rocha CS; Wiklander OP; Larsson L; Moreno PM; Parini P; Lundin KE; Smith CI
    J Mol Cell Cardiol; 2015 May; 82():186-93. PubMed ID: 25791168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of estrogen on serum level and hepatocyte expression of PCSK9.
    Guo W; Fu J; Chen X; Gao B; Fu Z; Fan H; Cui Q; Zhu X; Zhao Y; Yang T; Fan D; Zhou H
    Metabolism; 2015 Apr; 64(4):554-60. PubMed ID: 25665485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
    Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
    Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
    Basak A; Palmer-Smith H; Mishra P
    Protein Pept Lett; 2012 Jun; 19(6):575-85. PubMed ID: 22519528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9
    Lammi C; Bollati C; Lecca D; Abbracchio MP; Arnoldi A
    Nutrients; 2019 Jul; 11(7):. PubMed ID: 31330826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
    Syed GH; Tang H; Khan M; Hassanein T; Liu J; Siddiqui A
    J Virol; 2014 Mar; 88(5):2519-29. PubMed ID: 24352472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
    Romagnuolo R; Scipione CA; Boffa MB; Marcovina SM; Seidah NG; Koschinsky ML
    J Biol Chem; 2015 May; 290(18):11649-62. PubMed ID: 25778403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
    Fisher TS; Lo Surdo P; Pandit S; Mattu M; Santoro JC; Wisniewski D; Cummings RT; Calzetta A; Cubbon RM; Fischer PA; Tarachandani A; De Francesco R; Wright SD; Sparrow CP; Carfi A; Sitlani A
    J Biol Chem; 2007 Jul; 282(28):20502-12. PubMed ID: 17493938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.